检验医学与临床2024，Vol.21Issue(2)：203-207,212,6.DOI:10.3969/j.issn.1672-9455.2024.02.014
洛匹那韦/利托那韦联合α-干扰素治疗新型冠状病毒感染的疗效及对免疫功能的影响
Effect of lopinavir/ritonavir combined with interferon-α in treatment of 2019-ncov infection and its effect on immune function
摘要
Abstract
Objective To investigate the clinical efficacy and immune function of lopinavir/ritonavir(LPV/r)combined with interferon-α(INF-α)in the treatment of 2019-ncov infection,and to actively monitor the oc-currence of adverse drug reactions(ADR).Methods The clinical data of 270 patients with 2019-ncov infection from January 28 to June 17,2020 were retrospectively analyzed.According to the treatment drugs,the patients were divided into LPV/r group,INF-a group and combination group,with 90 cases in each group.The general data of all patients were collected and compared.The improvement time of clinical symptoms,nucleic acid neg-ative conversion time,and pulmonary imaging examination of all patients were counted and analyzed.The lym-phocyte count,CD4+T lymphocyte count and CD8+T lymphocyte count were compared among the three groups.The results of active monitoring of ADR in all patients were counted.Results Compared with LPV/r group and INF-α group,the antipyrexia time,respiratory symptoms relief time and nucleic acid negative con-version time were shortened,and the improvement rate of pulmonary imaging examination was increased in combination group,and the differences were statistically significant(P＜0.05).The lymphocyte count,CD4+T lymphocyte count and CD8+T lymphocyte count of the three groups after treatment were higher than those before treatment,and the differences were statistically significant(P＜0.05).Compared with the LPV/r group and the INF-α group,the lymphocyte count,CD4+T lymphocyte count and CD8+T lymphocyte count in the combined group were all increased,and the differences were statistically significant(P＜0.05).After com-prehensive evaluation by clinical pharmacists combined with patients'individual conditions,there was no sta-tistically significant difference in the correlation evaluation,severity classification and discharge outcome of ab-normal liver function among the three groups(P＞0.05).The number of patients with abnormal liver func-tion in the combined group was higher than that in the INF-α group,and the difference was statistically signif-icant(P＜0.05).There was no significant difference in the number of patients with abnormal liver function between the combined group and LPV/r group(P＞0.05).The total incidence of ADR in LPV/r group,INF-α group and combination group was 32.22％,12.22％and 37.78％respectively.The most common ADR inLPV/r group and combination group was cumulative digestive system,mainly characterized by diarrhea,nau-sea and vomiting,followed by rash/pruritus.Compared with the INF-αgroup,the LPV/r group and the combi-nation group had a significantly higher rate of diarrhea,a significantly higher number of digestive system adverse reactions,and a significantly higher total number of ADR patients(P＜0.05).There was no significant difference in the incidence of ADR between the LPV/r group and the combined group(P＞0.05).Conclusion LPV/r combined with INF-α can significantly improve the clinical efficacy of single drug in the treatment of 2019-ncov infec-tion,especially in shortening the time of nucleic acid clearance,improving the improvement rate of lung ima-ging and enhancing immune function.However,compared with INF-α,LPV/R combined with INF-α can pro-duce some adverse reactions,and the safety of LPV/R combined with INF-α should be taken seriously.关键词
新型冠状病毒感染/洛匹那韦/利托那韦/α-干扰素/药物不良反应/临床疗效/免疫功能Key words
2019-ncov infection/lopinavir/ritonavir/interferon-α/drug adverse reaction/clinical efficacy/immune function分类
医药卫生引用本文复制引用
倪薪,王茜,曲英杰,倪茗..洛匹那韦/利托那韦联合α-干扰素治疗新型冠状病毒感染的疗效及对免疫功能的影响[J].检验医学与临床,2024,21(2):203-207,212,6.基金项目
黑龙江省省属高等学校基本科研业务费科研项目(2020-KYYWFMY-0018). （2020-KYYWFMY-0018）
